Skip to Content
COVID-19 Response and Update

Everyone deserves access to essential medicines — that’s why we’re here

Amneal

We manufacture 290+ medicines for real people facing a wide range of conditions

We manufacture 290+ medicines for real people facing a wide range of conditions

Jane, struggling with migraine in Dallas, Texas.
David, struggling with opioid addiction in Madison, Wisconsin.
Gasper, living with Parkinson's disease in Norman, Oklahoma.
Watch full video

Gasper, living with
Parkinson's disease.

“I know I got it but I try to control it. [CREXONT®] gives me more freedom to do things, more confidence to do things.”

See the full story

Innovating access across complex generics, biosciences, and specialty medicines

For over 20 years, we’ve pushed the limits of what’s possible to make advanced medicines accessible to more people. Today, our portfolio spans 290+ high-quality pharmaceuticals, powered by new operational advances and an exceptionally skilled team.

All products

Fighting cancer
for less

Biosimilars(Opens in a new window)

Annually, saving people in the U.S.

$18B*

Enabling you to
save a life

Generics(Opens in a new window)

Giving you back “Good On” Time

Specialty(Opens in a new window)

Giving you back more “Good On” Time

*Calculated by taking the total 2023 national savings estimated by the Association for Accessible Medicines and determining Amneal’s market share by volume, data of which was derived from IQVIA

“Advocating for patient access and affordability is a responsibility I take personally. I'm proud to help shape policies that make life better for families and communities across the country.”

sig-photo

Maryll W Toufanian
Senior Vice President, Regulatory Strategy and Government Affairs

signature

Bringing manufacturing of essential medicines back to the U.S. is a big challenge that we’re taking on

Manufacturing

1 M

sq. ft. of advanced
manufacturing space in the U.S.

thumb-building

~2,500

number of U.S. jobs and
growing

map map yellpoint

Join us in making medicine accessible for all

Careers

Apply now

Open US roles(Opens in a new window)

871

Promotions in 2024

“This is a place where people and purpose thrive – where we grow together, tackle challenges with curiosity, and truly make a difference in people’s lives.” Nikita Shah, Executive Vice President, Chief Human Resources Officer

Amneal Named a 2026 BioSpace Best Places to Work Winner

Learn more(Opens in a new window)

Product updates
brekiya

Amneal Launches Brekiya® (dihydroergotamine mesylate) autoinjector for the Acute Treatment of Migraine and Cluster Headache Episodes in adults

See Warning. Do not take Brekiya autoinjector with strong CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. For full prescribing information, including BOXED WARNING, see our product labeling at Brekiya.com.

Product labeling Product website Press release

crexont

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease

The most common adverse reactions are nausea and anxiety. For full prescribing information, see our product labeling.

Product labeling Product website Press release

Important Label Information for Temozolomide Capsules, USP, 250 mg(Opens in a new tab)

News & press releases

© 2026 Amneal Pharmaceuticals LLC. All rights reserved.